HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007)

Figure 2

Antiviral activity of SRI-32007 against HBV genotype B in Huh7 cells. Huh7 cells transfected with HBV genotype B plasmid were treated with different concentrations of SRI-32007 in 96 wells for six days followed by measurement of HBe antigen in the culture supernatants by ELISA and cell viability using MTS. HBe Ag levels in the treated samples and cell viability normalized to the untreated samples (average ± standard deviation from triplicate samples) are shown in the figure.